RATIONALE: New diagnostic procedures, such as glycan analysis, may be effective in finding ovarian epithelial cancer. PURPOSE: This clinical trial is studying how well glycan analysis works in diagnosing cancer in women with ovarian epithelial cancer and in healthy female participants.
OBJECTIVES: Primary * Evaluate the accuracy of glycan analysis to distinguish between normal healthy control female subjects and those with ovarian epithelial cancer. Secondary * Compare the new assay to the standard CA 125 for diagnostic accuracy. OUTLINE: * Ovarian cancer patients: Blood samples are obtained periodically for up to 2 years. Patients undergoing surgery have blood samples drawn before and after surgery. Medical charts are reviewed periodically for up to 3 years. * Healthy volunteers: One blood sample is obtained. Volunteers also complete a 1-page questionnaire. PROJECTED ACCRUAL: A total of 300 healthy female participants and 400 patients will be accrued for this study.
Study Type
OBSERVATIONAL
Enrollment
581
University of California Davis Cancer Center
Sacramento, California, United States
Accuracy of glycan analysis
For healthy controls, a single sample will be obtained. For patients scheduled for surgery, two samples will be obtained: one preoperatively and one postoperatively. Ovarian cancer patients who agree to participate in the longitudinal study will have follow-up serum samples drawn periodically during chemotherapy treatments and then during surveillance visits, to correspond with routine blood testing for CA 125. They will be asked to participate for 2 years, with a maximum of 8 blood draws per year (to be coordinated with other venipunctures, if possible).
Time frame: one time for healthy volunteers; up to 2 years for patients with cancer
Comparison of the new assay to the standard CA 125 assay
For healthy controls, a single sample will be obtained. For patients scheduled for surgery, two samples will be obtained: one preoperatively and one postoperatively. Ovarian cancer patients who agree to participate in the longitudinal study will have follow-up serum samples drawn periodically during chemotherapy treatments and then during surveillance visits, to correspond with routine blood testing for CA 125. They will be asked to participate for 2 years, with a maximum of 8 blood draws per year (to be coordinated with other venipunctures, if possible).
Time frame: one time for healthy volunteers; up to 2 years for patients with cancer
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.